Lirafugratinib Included in NCCN Guidelines for Advanced Cholangiocarcinoma

Lirafugratinib has been added to the NCCN Clinical Practice Guidelines in Oncology for Biliary Tract Cancers. It is now a category 2A preferred subsequent-line therapy for patients with FGFR2 fusion or rearrangement-positive cholangiocarcinoma who have experienced disease progression. This inclusion follows the FDA approval of lirafugratinib on September 23, 2026, which was based on data from the phase 1/2 ReFocus trial, offering a new treatment option for this specific cancer type.